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Abstract
Background: Tissue repair and regeneration is assisted by the efficient coordina-
tion of cell and extracellular matrix interactions mediated by matricellular mole-
cules such as periostin. Given its high expression around the teeth, the
periodontal organ represents an ideal system to capture the protein dynamics
during wound healing.
Methods: An observational prospective case–control study was designed to char-
acterize periostin changes over time after periodontal surgery in tissue, oral fluids
and serum by histological, protein and mRNA analyses.
Results: Histological analysis showed lower periostin with a diffuse local
distribution pattern in disease patients. Levels of periostin in gingival
crevicular fluid (GCF) increased over time for both groups, more noticeably
in the periodontitis subjects. A transient and subtle change in circulating
periostin levels was also noticed. The mRNA periostin levels contrasted with
the protein levels and may indicate the underlying post-transcriptional
regulatory process during chronic inflammation. Levels of known
periodontal disease biomarkers such as IL-b, IL1-a, TNF-a, MIP-1a and CRP
served as tissue stability markers and complemented the clinical parameters
recorded.
Conclusion: The transient local increase in GCF periostin after eliminating
the local etiology in periodontally affected sites suggests its importance in the
maturation and stability of the connective tissue. The decreasing
levels observed as the tissue healed highlight its spatial/temporal
significance.
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Periostin is a multifaceted protein
implicated in numerous tissue
repair and regenerative processes.
Its role as a matricellular modula-
tor has triggered noteworthy efforts
to establish its value as a biomar-
ker for a number of diseases
(Sasaki et al. 2003, Ben et al. 2009,
Contie et al. 2010, 2011, Fujimoto
et al. 2011, Okamoto et al. 2011,
Nuzzo et al. 2014, Tian et al.
2014).
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A few variant forms of periostin
have been reported in the literature
but still little is known about their
specific functions (Takeshita et al.
1993, Horiuchi et al. 1999, Litvin
et al. 2004, Kim et al. 2008, Bai
et al. 2010). The larger, full-length
90 and 87-kDa known isoforms are
normally found to be secreted by
neuroectodermal- derived fibroblasts
(Horiuchi et al. 1999, Snider et al.
2008). Once it is secreted, periostin
has an affinity to bind to molecules
such as type I collagen, tenascin-C
and BMP-1 (Kii et al. 2010, Maru-
hashi et al. 2010). This affinity
assists in the maturation of the
extracellular matrix and favours
increase in tissue strength (Kii et al.
2006, Norris et al. 2007). In addi-
tion, periostin has been found to
possess potent mitogenic properties
via integrin receptor interactions. Its
association with the avß3 integrin
receptor has been found to support
AKT/PKB signalling, increasing
fibroblast and epithelial/endothelial
migration as well as activating the
mTOR signalling pathway leading to
proliferation (Rosselli-Murai et al.
2013, Padial-Molina et al. 2014).
Similar to other highly homologous
proteins such as bigH3, periostin
expression is regulated by TGF-ß in
response to mechanical stimulation
(Rios et al. 2008). Collectively, the
body of evidence regarding periostin
has helped us to understand the key,
pivotal role of this molecule as an
orchestrator of the tissue response to
environmental demands.
The study and characterization of
periostin null mouse models became a
turning point for this field of research.
The periodontal phenotype clearly
illustrated the importance of periostin
in tissue stability and its response to
injury. Although no human mutation
resulting in complete depletion of
periostin is known nor have physio-
logical levels of periostin been
reported for patients, a normal
threshold that modulates the biome-
chanical competency of the periodon-
tal extracellular matrix (ECM) can be
assumed. Interestingly, the primary
aetiological factors for the most com-
mon human inflammatory condition
that affects the adult dentition has a
suppressive effect on periostin. Both
bacterial byproducts and inflamma-
tory cytokines exert a negative
effect on periostin expression by
periodontal ligament (PDL) fibrob-
lasts and as a consequence, defects in
the ECM occur and compromise the
structural and functional integrity of
the tooth-supporting apparatus
(Padial-Molina et al. 2012b, 2013).
Therefore, an increase in periostin
levels after surgical treatment or by
active delivery can be hypothesized to
improve periodontal wound healing
and regeneration due to its properties
in stabilizing the ECM and promot-
ing periodontal tissue cell activity.
Subsequently, the human periodontal
disease condition serves as an ideal
model to learn how neuroectodermal-
derived cells such as the periodontal
fibroblasts cope with the trauma
associated with surgery during the
initial phases of wound healing and
support a periostin expression profile
that moves the healing process
forward.
The overarching goal of this
study was to capture the periostin
expression profile that favours
wound stability and maturation. The
periodontal disease condition serves
as the chronic burden that challenges
the host and prevents proper matri-
cellular function and therefore
favouring a long-lasting infection.
Our study is designed to characterize
the expression of periostin in health
and disease and to analyze its chron-




An observational prospective case–
control study was designed and
approved by the University of
Michigan Institutional Review
Board. The trial is registered at
ClinicalTrials.gov, number NCT011-
80920.
Participants (Inclusion and exclusion)
Subjects from the Michigan Center
for Oral Health Research (MCOHR)
were evaluated after obtaining the
appropriate informed consent.
Adults aged 21 years and above of
both genders were eligible for the
study. For disease subjects (case
group), a diagnosis of generalized
chronic or aggressive periodontitis,
presence of at least four periodontal
sites with probing depth (PD)
≥6 mm, evidence of clinical attach-
ment loss (CAL), >10% of sites with
bleeding on probing (BOP) and need
of an open flap debridement were
established as the inclusion criteria.
Inclusion criteria for healthy individ-
uals (control group) included PD
<4 mm, no evidence of attachment
loss, <10% of sites with BOP and
need of a gingivectomy or crown
lengthening procedure. Candidates
were excluded if they presented his-
tory of alcoholism or drug abuse;
medical conditions that may affect
the outcome of periodontal surgery
such as autoimmune diseases, dia-
betes, immunocompromised subjects
or systemic infections; chronic
medications known to affect the
periodontal status such as cal-
cium antagonists, anticonvulsives,
immunosuppressives, anti-inflamma-
tory medications or contraceptives;
antibiotic therapy within 3 months
of the baseline visit; antibiotic ther-
apy needed for infective endocarditis
prophylaxis; current use or those
who quit smoking less than
6 months ago with a pack-year his-
tory of more than or equal to 10;
current dental conditions, including
orthodontic treatment (presence of
orthodontic devices), insufficient ker-
atinized gingival (equal or less than
2 mm), untreated carious lesions or
defective restorations which could
exacerbate.
A total of 185 patients showed
interest in participating in the study
and were assessed for eligibility.
Eighty two did not meet the inclu-
sion criteria, 13 declined to partici-
pate and 68 were excluded for other
reasons, including scheduling con-
cerns, other concomitant treatment
needs that would be better treated in
the same procedure and patients
already participating in any other
studies. About 22 patients were
enrolled in this study, 11 in need of a
gingival flap and tooth root instru-
mentation (chronic periodontal
inflammation/infection group) and
11 in need of a gingival re-contouring
procedure (non-inflamed/Periodon-
tally stable group). None of them
were lost to follow-up, discontinued
the treatment for any reason or suf-
fered any adverse event. Figure 1a
represents the CONSORT flow dia-
gram of patients in the study.
Patient demographics and main
variables distribution were homoge-
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neous between the two groups and
representative of the local popula-
tion in terms of ethnic group (self-
reported) (Table 1). No significant
differences were found among
groups for any of these variables.
Study timeline and sample collection
At baseline, tissue biopsies were
collected from the selected sites
during the necessary periodontal sur-
gery. Additionally, GCF/wound fluid
(immediately before and after the
procedure), whole saliva (WS) and
serum were collected. Patients were
prescribed an over-the-counter
analgesic and an antibiotic when
needed. Oral and written post-surgi-
cal recommendations were given.
After the surgery, GCF/wound fluid
and WS samples were collected at
24 h, 48 h, 2 wk and 4 wk. Addi-
tional serum samples were collected
at 2 wk and 4 wk. See Fig. 1b for
study timeline.
Refer to Appendix S1 for com-
plete sample collection and analysis
methodology.
Outcomes
The samples were processed appro-
priately to analyse each one of the
different variables. Different por-
tions of tissue were analysed by
immunohistochemistry (for periostin
protein localization), ELISA (for
protein levels of periostin) or qRT-
PCR (for levels of periostin mRNA).
Protein levels of periostin were also
analysed by ELISA in GCF/wound
fluid, WS and serum. In addition,
GCF/wound fluid was also used for
the analysis of periodontal disease-
related cytokines (CRP, IL-1a,
IL-1ß, IL-6, IL-8, IL-10, MIP-1a,
Osteopontin, Osteoactivin, MMP-9,
MMP-13 and TNF-a) by using an
array-based multiplex ELISA sys-
tem. Finally, clinical measurements
were used to evaluate changes over
time in PD, CAL, oral hygiene, dis-
comfort, soft tissue index and wound
healing index.
Statistical methods (Power analysis)
An inter-rater reliability analysis
using the Kappa statistic was per-
formed to determine consistency
among raters for all clinical parame-
ters. Additionally, intra-rater test–
retest reliability was also assessed by
Pearson’s correlation test. Demo-
graphic data is reported as prevalence
of categorical data and differences
analysed by Pearson’s v2 test. Unless
otherwise specified, continuous data
is reported as mean (SD). Compar-
isons within groups were made by
paired t-test. Comparisons among
groups were made by independent t-
test. Additionally, to analyse differ-
ences within groups over time for
periostin in GCF/wound fluid and
serum, a repeated measures ANOVA
test was designed (with Greenhouse–
Geisser correction if a significant
Mauchly’s test indicates a violation
of sphericity). Level of statistical sig-
nificance was established at p < 0.05.
Given that periostin has never been
evaluated in oral fluids, we chose to
extrapolate findings from other dis-
ease entities. We have identified the
effect size as part of the initial power
analysis to establish a proper sample
size estimated to be 20 ng/ml with a
(a)
(b)
Fig. 1. Study design. (a) CONSORT diagram of study participants. (b) Diagram of
study procedures.
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value of 0.05 and 80% power. This
determination was based on periostin
levels reported in the cancer literature
from healthy patients (~30 ng/ml)
and diseased patients (~50 ng/ml).
Results
Clinical results
Examiner calibration between the
examiner and the standard examiner
showed a 90.68% of exact agreement
pairs with a j = 0.876 (95% CI,
0.944 to 0.807) (p < 0.0005) for PD
and a 63.56% of exact agreement
pairs with a j = 0.552 (95% CI,
0.651 to 0.452) (p < 0.0005) for
CAL. Intra-examiner reliability was
100% for both the PD and CAL.
Clinical measurements (in mm)
showed statistically significant differ-
ences for independent comparisons
of PD [3.0 (0.9) versus 6.7 (1.9); 2.3
(0.8) versus 3.9 (1.0)] and CAL [2.3
(0.9) versus 6.5 (2.0); 2.8 (0.6) versus
4.8 (1.3)] (healthy versus disease at
baseline and 4 weeks respectively),
and PD change [0.7 (1.0) versus 2.8
(1.3)] and CAL change [0.5 (1.1)
versus 1.7 (2.0)] (healthy versus dis-
ease) (p < 0.001, Independent t-test).
Within groups, PD at baseline was
significantly different than PD at
4 weeks (paired t-test) for both
healthy (p < 0.038) and disease
groups (p < 0.0005), and CAL from
baseline to 4 weeks in the disease
group (p < 0.015) (Fig. 2).
As expected, qualitative clinical
variables showed a progressive
improvement over time for all
variables analysed (Oral hygiene,
Discomfort, Soft tissue index and
Wound healing index) (Fig. S1).
Oral hygiene worsened from 24 h to
48 h, which was expected as
patients were instructed to not
brush the area of the surgery during
the first 5 days.
Periostin in tissue
Histological analysis of the tissues
collected from the healthy periodon-
tium during the surgical procedures
(Fig. 3) showed that the periostin
immunoreactivity signal highlights a
robust distribution and localization
of the secreted protein in the under-
lying specialized connective tissue
right beneath the junctional epithe-
lium. A fibrillar pattern of periostin
distribution was observed. Such
observation is similar to the fibrillar
structure and directionality of the
periodontal ligament to the alveolar
bone and the tooth root surface.
The hematoxylin & eosin (H&E)
staining showed no relevant inflam-
matory infiltrate but the normal
characteristics of a healthy epithe-
lium, junctional epithelium and con-
nective tissue. In contrast, the tissue
samples from periodontal disease
Table 1. Demographic variables
Healthy – n = 11 Disease – n = 11 Pearson’s v2
Age – years
Median 39 51 0.232
Range 22–70 29–71
Sex – n (%)
Male 8 (73) 7 (64) 0.647
Female 3 (27) 4 (36)
Race or ethnic group – n (%)*
Caucasian 8 (73) 9 (82) 0.383
African American 1 (9) 1 (9)
Asian 0 (0) 1 (9)
Hispanic 2 (18) 0 (0)
Native American 0 (0) 0 (0)
Other 0 (0) 0 (0)
Smoking status – n (%)
Never Smoked 7 (64) 7 (64) 1.000
Former Smoker (>6 months) 4 (36) 4 (36)





Fig. 2. Clinical measurements (mean  SEM) of (a) Probing depth and (b) Clinical
attachment level at baseline and 4 weeks, as well as (c) Probing depth and (d) Clinical
attachment level change from baseline to 4 weeks. *p < 0.001 (Independent t-test);
+p < 0.001; ++p < 0.038; +++p < 0.015 (Paired t-test).
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patients showed overall lower and
diffuse pattern of extracellular peri-
ostin incorporation in the area
beneath the functional epithelium.
As expected, a localized chronic
inflammatory infiltrate front was vis-
ible in the H&E sections and colo-
calized with the areas of diffuse
periostin signal.
The whole tissue lysates con-
trasted with the detailed morpholog-
ical description of periostin protein
distribution feasible by the available
tissue sections. As a limitation
determined by the biopsy collection
method, when assessing periostin
protein levels in the whole tissue
sample lysate (in ng/ml), those spa-
tial differences were washed away
and no statistical significant differ-
ences comparing the healthy [42.559
(23.696)] and the disease samples
were observed [38.133 (19.631)] (p =
0.639, Independent t-test) (Fig. S2).
Similarly, mRNA analysis of the
whole tissue lysate showed no statis-
tically significant differences of peri-
ostin [1.00 (0.87) versus 1.902 (2.20);
p = 0.221], bIG-H3 [1.00 (0.73)
versus 0.951 (0.67); p = 0.870], colla-
gen I [1.00 (0.61) versus 2.51 (3.92);
p = 0.233], Twist [1.00 (0.64) versus
1.46 (0.94); p = 0.192] and TGF-b1
[1.00 (0.32) versus 1.20 (0.54);
p = 0.306] when comparing healthy
versus disease groups (Independent
t-test) (Fig. S3).
Periostin protein in GCF/wound fluid and
serum
Levels of periostin in GCF/wound
fluid (in pg/ml) (Fig. 4a) increased
over time and correlated with the
healing process in both healthy and
disease patients. A repeated mea-
sures ANOVA with a Greenhouse–
Geisser correction [Mauchly’s Test
of Sphericity: v2 (14) = 28.947,
p < 0.013] determined that mean
periostin concentration in the disease
group was statistically significant
between time points [F (5.252,
27.246) = 2.725, p < 0.007]. Post hoc
tests using the Bonferroni correction
revealed that periostin levels previ-
ous to the surgery [367.85 (418.87)]
were statistically significantly lower
than those at 48 h [1496.14 (747.48),
p < 0.001] and 2 weeks [836.80
(199.606), p < 024]. In healthy sub-
jects, the repeated measures ANOVA
with a Greenhouse–Geisser correc-
tion [Mauchly’s Test of Sphericity:
v2 (14) = 70.908, p < 0.0005] showed
no statistically significant differences
over time [F (1.226, 12.264) = 1.829,
p = 0.203] and therefore, post hoc
comparisons were not performed.
Differences among groups were sta-
tistically significantly different only
immediately post-surgery [354.68
(452.22) versus 1158.31 (1041.72);
p < 0.029] and at 48 h [798.24
(306.47) versus 1496.14 (747.48);
(a) (b) (c)
(d) (e) (f)
Fig. 3. Representative images of the tissue histological analysis for both healthy (a, b,
c) and disease patients (d, e, f) by hematoxylin-eosin (a, b, d, e) and periostin stainings
(c, d) captured at an original magnification of 29 (a, d) and 409 (b, c, e, f) in the area
of interest (insert in a and d below the junctional epithelium).
(a) (b)
Fig. 4. Levels of periostin (mean  SEM) over time for healthy (blue) and diseased
(red) patients expressed as mean  SEM in (a) GCF/wound fluid (pg/ml) [*p < 0.001;
**p < 0.024 (Bonferroni post hoc); +p < 0.029; ++p < 0.013 (Independent t-test] and
(b) serum (ng/ml) [#p < 0.001; ##p < 0.0005; ^p < 0.015; ^^p < 0.020 (Bonferroni post
hoc)].
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p < 0.013] (healthy versus disease;
Independent t-test).
Periostin levels in serum (Fig. 4b)
showed a reduction from baseline
[267.58 (88.77) versus 319.04 (280.43);
p = 0.568] to 2 weeks [177.64 (43.26)
versus 227.59 (207.96); p = 0.445] and
went back to initial values at 4 weeks
[249.79 (65.76) versus 289.69 (261.07);
p = 0.628] (healthy versus disease;
Independent t-test) in both groups.
Repeated measures ANOVA with
sphericity assumption [Mauchly’s
Test of Sphericity: v2 (2) = 2.061,
p = 0.357] determined that the mean
periostin concentration in serum in
the healthy group differed statistically
significant between time points [F (2,
20) = 21.122, p < 0.0005]. Post hoc
tests using the Bonferroni correction
revealed that periostin levels at
2 weeks were statistically significantly
lower to those detected prior to the
surgery (p < 0.001) and at 4 weeks
(p < 0.0005). Similarly, repeated
measures ANOVA with a Greenhouse–
Geisser correction [Mauchly’s Test of
Sphericity: v2 (2) = 5.022, p = 0.081]
determined that mean periostin
concentration in serum in the dis-
ease group differed statistically
significantly between time points [F
(1.401, 14.009) = 10.914, p < 0.003].
Post hoc tests using the Bonferroni
correction revealed that periostin
levels at 2 weeks were statistically sig-
nificantly lower to those detected
prior to the surgery (p < 0.015) and
at 4 weeks (p < 0.020).
Periostin protein was unde-
tectable in saliva in the present
study.
Periodontal disease-related cytokines in
serum and GCF/wound fluid
The CRP in serum (Fig. S4) and peri-
odontal disease-related cytokines in
GCF/wound fluid (Fig. 5) follows a
similar pattern as in other previously
published studies (Kinney et al.
2007). In this sense, it is interesting to
note the differences between baseline
and 4-weeks time points for CRP, IL-
1a, IL-1ß, and TNF-a, specifically in
disease patients. Those levels became
similar to those obtained in healthy
patients, indicating the resolution of
the disease process.
Discussion
Besides the periodontium, the matri-
cellular molecule periostin has been
recognized as a pivotal participant
in the functional stability of multi-
ple systems. In general, it has been
shown that the larger, full-length 90
and 87-kDa isoforms are normally
secreted by cells such as neuroecto-
dermal-derived fibroblasts (Horiuchi
et al. 1999, Snider et al. 2008). Tis-
sue-specific isoforms are thought to
be modulators of respective tissues.
In the PDL, the large full-length
variants have been reported to regu-
late FAK signalling and potentially
influenced mineralization when over
Fig. 5. Levels of periodontal disease markers over time in GCF/wound fluid in pg/ml (mean  SEM) for healthy (blue) and disease
(red) patients.
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expressed in vitro (Yamada et al.
2014). It is speculated that these
isoforms are downstream responders
along the PDL differentiation path-
way. Therefore, in the context of
wound healing after surgery, its
expression profile should be tran-
sient (i.e. switched off after differen-
tiation or as PDL inflammation
diminishes) while if it stays
expressed, normal tissue function
could be compromised (Conway
et al. 2014).
The timely and spatially sensitive
regulation of matricellular interac-
tions determines the adaptive, repar-
ative and regenerative response by
modulating function among impor-
tant growth factors, cytokines and
proteases (Hamilton 2008), therefore,
allowing proper healing and func-
tion. The currently known functional
features of periostin together with
the findings of this study supports
that this matricellular molecule does
not passively follow the extracellular
matrix response to trauma. Instead,
it seems to critically modulate
inflammatory and reparative path-
ways by transducing signals that
affect cell survival, migration and
matrix maturation along with pheno-
type and gene expression at active
sites of tissue repair and regenera-
tion. Similarly to what has been
seen in the injured heart (Conway &
Molkentin 2008), in the periodon-
tium, periostin is released by specia-
lized fibroblasts to regulate cellular
interactions and promote matrix
organization.
Of the known proteins expressed
in the PDL, periostin shows the
greatest specificity (Saito et al. 2002).
It is localized between the cytoplas-
mic processes of periodontal fibrob-
lasts and cementoblasts and the
adjacent collagen fibrils (Suzuki
et al. 2004). It has been, therefore,
used as a marker of successful peri-
odontal regeneration (Park et al.
2012, 2014). When absent in KO
mice, a periodontal disease-like
phenotype compared to wild-type
animals can be observed (Rios et al.
2008). Similarly, periodontal disease
causal factors reduce the localization
of periostin in the periodontal liga-
ment, both in vitro (Padial-Molina
et al. 2013) and in vivo (Padial-
Molina et al. 2012b). However, acute
exposure to the same pro-inflamma-
tory factors (TNF-a and P. gingivalis
LPS) seems to induce its secretion
from gingival fibroblasts (Nakajima
et al. 2014). The different cell popu-
lations involved in each phase of the
disease may explain this apparent
discrepancy. At the gingival epithe-
lial level, periostin promotes an
increased proliferation and migration
rate similar to that observed in skin
epithelial cells as a potential enhan-
cer of wound closure after injury
(Rosselli-Murai et al. 2013). Simi-
larly, epithelial cells, as the first front
of defence in periodontal tissues,
increase periostin release to promote
gingival sealing around the teeth in
response to bacteria. In contrast, as
the disease progresses, the inflamma-
tory process evolves and reaches the
sub-gingival connective tissue and
periodontal ligament. Then, those
factors promote a reduction of peri-
ostin, which additively weakens the
tissue and, therefore, disease pro-
gression is accelerated. According to
our results, differences in periostin
localization in the tissue by immuno-
histological analysis were present
(Fig. 3). However, analyses of the
gingival fluid (Fig. 4a) or the whole
tissue lysate (Figs S2 and S3) at
baseline did not show such differ-
ences, possibly due to the masking
effects induced by other surrounding
tissues. Additionally, patients
included in this study presented
different types and severities of the
disease. Consequently, the use of
periostin as a marker of periodontal
disease could not be concluded from
the present study, although a recent
report suggests this correlation (Balli
et al. 2014); the study showed that
periostin levels in gingival crevicular
fluid decreased proportionally with
the progression and severity of
periodontal disease, and negatively
correlated with the clinical parame-
ters. Interestingly, periostin in serum
was higher in diseased patients,
which correlates with our findings of
an inverse correlation between peri-
ostin levels in serum and GCF/
wound fluid. Further studies are still
needed, specifically in aggressive
cases, where some differences were
observed in GCF/wound fluid.
Periodontal wound healing and
homeostasis requires the migration
to the area of specific cells, at a
specific time, in a specific sequence
(Padial-Molina et al. 2012a). Perios-
tin is essential in these processes
(Hamilton 2008) by regulating
collagen fibrillogenesis, which influ-
ences tissue mechanical stability
and strength (Norris et al. 2007).
Moreover, periostin activates the cell
survival AKT/PKB/mTOR pathway
(Rosselli-Murai et al. 2013, Padial-
Molina et al. 2014) and induces
migration and proliferation through
the interaction with avb3 and avb5-
integrins (Li et al. 2010, Utispan
et al. 2012). Similar effects have been
previously reported in other tissues,
including skin (Nishiyama et al.
2011), heart (Dorn 2007, Kuhn et al.
2007, Polizzotti et al. 2012), during
angiogenesis (Zhu et al. 2010) and
metastasis (Wang & Ouyang 2012).
Therefore, restoration of proper
levels of this molecule in the PDL
environment may have key implica-
tions in the restoration of its original
structure and function, specifically
after periodontal surgery, with
potential use as a regenerative agent.
Our results show a statistically sig-
nificant increase of periostin after
periodontal surgery in GCF/wound
fluid, being greater in disease
patients (Fig. 4a). This increase is
explained by the reduction of
chronic inflammatory stimuli and
bacterial challenge as a consequence
of surgical procedure. Periostin
increases temporarily to assist in the
healing process by increasing cell
migration and proliferation, and in
the establishment of a stable extra-
cellular matrix. As the wound
matures, levels of periostin detect-
able in GCF/wound fluid are
reduced back to baseline levels, pos-
sibly due to a higher rate of deposit
of periostin in the extracellular
matrix as the collagen structure
matures. Similar effects have been
previously observed in vitro (Padial-
Molina et al. 2013).
In contrast, periostin in serum is
significantly reduced by 2 weeks and
back to baseline levels at 4 weeks fol-
lowing a similar pattern in both
healthy and disease patients (Fig. 4b).
Serum levels of periostin are currently
under study in a wide variety of sys-
temic diseases, including asthma (Mat-
sumoto 2014), myocardial infarction
(Ling et al. 2014), atherosclerosis
(Hakuno et al. 2010), atopic dermati-
tis (Kou et al. 2014), bone metabolism
(Rousseau et al. 2014), different can-
cers and others. This reflects the
implications of systemic periostin in a
© 2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd
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number of pathologies broader than
the limited localized surgery per-
formed in our study. However, the sig-
nificant changes observed over time in
the present study, in the absence of
any other change in the patients’ sys-
temic conditions, reflects the influence
of the periodontal status on the levels
of periostin being released into the
blood stream, which may have impor-
tant implications in distant tissues and
systemic pathologies.
The study of periostin thus pro-
vides a unique opportunity to learn
more about healing dynamics in dif-
ferent conditions. Extrapolating the
findings reported in this study could
have significant implications in aid-
ing our understanding of cell–matrix
dynamics and homeostasis in differ-
ent systems. Unravelling this perios-
tin-mediated matricellular pathway
provides an opportunity to explore
and could ultimately help us to
develop practical therapeutic proto-
cols that may impact and predictably
favour regeneration over repair
wound healing outcomes across
different human conditions.
Conclusion
The increase in periostin levels over
time in GCF/wound fluid suggests a
potential implication in the healing
process after periodontal surgery in
patients. Periostin follows a transient
but pronounced increase after sur-
gery in periodontally affected sub-
jects that is maintained for 2 weeks
but appears to peak at 48 h. This
expression profile suggests a role for
this molecule on moving the granu-
lation phase of wound healing
forward where recruitment, angio-
genesis and proliferative events are
essential to provide a better local
environment that leads the wound
healing process into optimal tissue
maturation and wound stabilization.
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Scientific rationale for the study:
Periodontal disease is a multifacto-
rial process. Extracellular matrix
and matricellular interactions are
key for tissue homeostasis and,
therefore, highly relevant to disease
pathogenesis and tissue healing.
Periostin, a highly specific matricel-
lular protein of the periodontal
ligament, has been shown to be
determinant in previous animal
studies.
Principal findings: This study indi-
cates that periostin plays a determi-
nant role in periodontal tissue healing
as it increases after periodontal
surgery in gingival crevicular fluid.
Practical implications: Periostin
basal levels could potentially be
used as a biomarker of periodontal
disease susceptibility and a healing
potential determinant. Future stud-
ies will confirm its promising appli-
cation as a regenerative agent.
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